Abstract
Amino acids related to neurotransmitters and the GABAergic/glutamatergic system were measured using a 3 T-MRI instrument in 12 patients with autism and 10 normal controls. All measurements were performed in the frontal lobe (FL) and lenticular nuclei (LN) using a conventional sequence for n-acetyl aspartate (NAA) and glutamate (Glu), and the MEGA-editing method for GABA. The GABA level and [GABA]/[NAA] ratio were significantly lower (p < 0.01) in the FL, but not the LN, in patients with autism compared to normal controls. The [GABA]/[Glu] ratio in the FL was also significantly lower (p < 0.05) in the patients than in the normal controls, thus suggesting a possible abnormality in the regulation between GABA and Glu.
Similar content being viewed by others
References
Aasly, J., Silfvenius, H., Aas, T. C., Sonnewald, U., Olivecrona, M., Juul, R., et al. (1999). Proton magnetic resonance spectroscopy of brain biopsies from patients with intractable epilepsy. Epilepsy Research, 35, 211–217.
Aldred, S., Moore, K. M., Fitzgerald, M., & Waring, R. H. (2003). Plasma amino acid levels in children with autism and their families. Journal of Autism and Developmental Disorders, 33, 449–454.
Baslow, M. H. (2003). N-acetylaspartate in the vertebrate brain: Metabolism and function. Neurochemical Research, 28, 941–953.
Bauman, M., & Kemper, T. L. (1985). Histoanatomic observations of the brain in early infantile autism. Neurology, 35, 866–874.
Choi, C., Bhardwaj, P. P., Kalra, S., Casault, C. A., Yasmin, U. S., Allen, P. S., et al. (2007). Measurement of GABA and contaminants in gray and white matter in human brain in vivo. Magnetic Resonance in Medicine, 58, 27–33.
Choi, I.-Y., Lee, S.-P., Merkle, H., & Shen, J. (2006). In vivo detection of gray and white matter differences in GABA concentration in the human brain. NeuroImage, 33, 85–93.
Cook, E. H., Courchesne, R. Y., Cox, N. J., Lord, C., Gonen, D., Guter, S. J., et al. (1998). Linkage-disequilibrium mapping of autistic disorder, with 15q11–13 Markers. American Journal of Human Genetics, 62, 1077–1083.
Cote, C. J., & Wilson, S. (2006). Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: An update. Pediatrics, 118, 2587–2602.
Devito, T. J., Drost, D. J., Neufeld, R. W., Rajakumar, N., Pavlosky, W., Williamson, P., et al. (2007). Evidence for cortical dysfunction in autism: A proton magnetic resonance spectroscopic imaging study. Biological Psychiatry, 61, 465–473.
Fatemi, S. H., Folsom, T. D., Reutiman, T. J., Thuras, P. D. (2008). Expression of GABAB receptors is altered in brains of subjects with autism. Cerebellum Nov 12 (Epub ahead of print).
Fatemi, S. H., Halt, A. R., Stary, J. M., Kanodia, R., Schulz, S. C., & Realmuto, G. R. (2002). Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biological Psychiatry, 52, 805–810.
Fatemi, S. H., Reutiman, T. J., Folsom, T. D., & Thuras, P. D. (2009). GABAA receptor downregulation in brains of subjects with autism. Journal of Autism and Developmental Disorders, 39, 223–230.
Friedman, S. D., Shaw, D. W. W., Artru, A. A., Dawson, G., Petropoulos, H., & Dager, S. R. (2006). Gray and white matter brain chemistry in young children with autism. Archives of General Psychiatry, 63, 786–794.
Friedman, S. D., Shaw, D. W., Artru, A. A., Richards, T. L., Gardner, J., Dawson, G., et al. (2003). Regional brain chemical alterations in young children with autism spectrum disorder. Neurology, 60, 100–107.
Guptill, J. T., Booker, A. B., Gibbs, T. T., Kemper, T. L., Bauman, M. L., & Blatt, G. J. (2007). [3H]-FLunitrazepam-labeled benzodiazepine binding sites in the hippocampal formation in autism: A multiple concentration autoradiographic study. Journal of Autism and Developmental Disorders, 37, 911–920.
Harada, M., Kubo, H., Nose, A., Nishitani, H., Matsuda, T. (in press) Measurement of variation in the human cerebral GABA level by in vivo MEGA-editing proton MR spectroscopy using a clinical 3 Tesla instrument and its dependence on brain region and the female menstrual cycle. Hum Brain Mapp.
Harada, M., Miyoshi, H., Uno, M., Okada, T., Hisaoka, S., Hori, A., et al. (1999). Neuronal impairment of adult moyamoya disease detected by quantified proton MRS and comparison with cerebral perfusion by SPECT with Tc-99m HM-PAO: A trial of clinical quantification of metabolites. Journal of Magnetic Resonance Imaging, 10, 124–129.
Hisaoka, S., Harada, M., Nishitani, H., & Mori, K. (2001). Regional magnetic resonance spectroscopy of the brain in autistic individuals. Neuroradiology, 43, 496–498.
Jensen, J. E., de Frederick, B., & Renshaw, P. F. (2005). Gray and white matter GABA level difference in the human brain using two-dimensional J-resolved spectroscopic imaging. NMR Biomed, 18, 570–576.
Lam, K. S. L., Aman, M. G., & Arnold, L. E. (2006). Neurochemical correlates of autistic disorder: A review of the literature. Research in Developmental Disabilities, 27, 254–289.
Levitt, J. G., O’Neill, J., McCracken, J. T., Guthrie, D., Toga, A. W., & Alger, J. R. (2003). Proton magnetic resonance spectroscopic imaging in childhood autism. Biological Psychiatry, 54, 1355–1366.
Lotspeich, L. J., & Ciaranello, R. D. (1993). The neurobiology and genetics of infantile autism. International Review of Neurobiology, 35, 87–129.
Ma, D. Q., Whitehead, P. L., Menold, M. M., etMartin, E. R., Ashley-Koch, A. E., Mei, H., et al. (2005). Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am J Hum Genet, 77, 377–388.
Meshcer, M., Merkle, H., Kirsch, J., Garwood, M., & Gruetter, R. (1998). Simultaneous in vivo spectral editing and water suppression. NMR in Biomedicine, 11, 266–272.
Murphy, D. G., Critchley, H. D., Schmitz, N., MacAlonan, G., van Amelsvoort, T., Robertson, D., et al. (2002). Asperger syndrome: A proton magnetic resonance study of brain. Archives of General Psychiatry, 59, 885–891.
Novotny, E. J., Jr., Hyder, F., Shevell, M., & Rothman, D. L. (1999). GABA changes with vigabatrin in the developing human brain. Epilepsia., 40, 462–466.
Otsuka, H., Harada, M., Mori, K., Hisaoka, S., & Nishitani, H. (1999). Brain metabolites in the hippocampus-amygdala region and cerebellum in autism: An 1H-MR spectroscopy study. Neuroradiology, 41, 517–519.
Oz, G., Terpstra, M., Tkac, I., Aia, P., Lowary, J., Tuite, P. J., et al. (2006). Proton MRS of the unilateral substantia nigra in the human brain at 4 Tesla: Detection of high GABA concentrations. Magnetic Resonance in Medicine, 55, 296–301.
Page, L. A., Daly, E., Schmitz, N., Simmons, A., Toal, F., Deeley, Q., et al. (2006). In vivo 1H-magnetic resonance spectroscopy study of amygdale-hippocampal and parietal regions in autism. American Journal of Psychiatry, 163, 2189–2192.
Petroff, O. A. C., Behar, K. L., Mattson, R. H., & Rothman, D. L. (1996). Human brain γ-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. Journal of Neurochemistry, 67, 2399–2404.
Petroff, O. A. C., Ogino, T., & Alger, J. R. (1988). High-resolution proton magnetic resonance spectroscopy of rabbit brain: Regional metabolite levels and postmortem changes. Journal of Neurochemistry, 51, 163–171.
Petroff, O. A. C., Rothman, D. L., Behar, K. L., & Mattson, R. H. (1995). Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of γ-aminobutyric acid, glutamate, and glutamine in human brain. Epilepsia, 36, 457–464.
Pouwels, P. J. W., Brockmann, K., Kruse, B., Wilken, B., Wick, M., Hanefeld, F., et al. (1999). Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS. Pediatric Research, 46, 474–485.
Provencher, S. E. (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine, 30, 672–679.
Samaco, R. C., Hogart, A., & Lasalle, J. M. (2004). Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Human Molecular Genetics, 14, 483–492.
Shinohe, A., Hashimoto, K., Nakamura Tsujii, M., Iwata, Y., Tsuchiya, K. J., Sekine, Y., et al. (2006). Increase serum levels of glutamate in adult patients with autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30, 1472–1477.
Terpstra, M., Henry, P.-G., & Gruetter, R. (2003). Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra. Magnetic Resonance in Medicine, 50, 19–23.
Terpstra, M., Ugurbil, K., & Gruetter, R. (2002). Direct in vivo measurement of human cerebral GABA concentration using MEGA-editing at 7 Tesla. Magnetic Resonance in Medicine, 47, 1009–1012.
Weber, O. M., Verhagen, A., Duc, C. O., Meier, D., Leenders, K. L., & Boesiger, P. (1999). Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. Magnetic Resonance Imaging, 17, 417–425.
Acknowledgments
This study was supported by a Grant-in-Aid for Scientific Research (B) No. 19390321 form the Japan Society for the Promotion of Science (JSPS) and a Grant from the Japanese Society of Neuroradiology.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harada, M., Taki, M.M., Nose, A. et al. Non-Invasive Evaluation of the GABAergic/Glutamatergic System in Autistic Patients Observed by MEGA-Editing Proton MR Spectroscopy Using a Clinical 3 Tesla Instrument. J Autism Dev Disord 41, 447–454 (2011). https://doi.org/10.1007/s10803-010-1065-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10803-010-1065-0